Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2015

View Archived Issues

Remotely regulated gene exression system devised to study disease

New NaV1.7 inhibitor identified for the treatment of pain

Sigma-Tau products granted FDA orphan status

Elafin shows potential as a biomarker to distinguish GVHD from EM

Researchers identify INSM1 as a sensitive marker of MCC

FDA gives ganaxolone orphan status for PCDH19 female epilepsy

University of Illinois patent describes new antimicrobials

Bristol-Myers Squibb presents PD-1/PD-L1 interaction inhibitors

Oxford Pharmascience reports topline data from pilot study of OXPzero Naproxen

Toray describes highly potent alpha1L-adrenoceptor agonists

100,000 Genomes Project aims to accelerate the development of new diagnostics and treatments

Novel GPBAR1 agonists synthesized for the treatment of diabetes and metabolic syndrome

ZeClinics seeks investment to develop zebra fish-based ZeOncoTest

Shire and Cincinnati Children's Hospital Medical Center to collaborate on rare disease therapies

Aldeyra Therapeutics starts phase II trial of NS-2 for non-infectious anterior uveitis

Japanese approval for Lenvima for unresectable thyroid cancer

Aduro BioTech cancer vaccine given orphan status for mesothelioma

Avalanche Biotechnologies and University of Washington collaborate to treat color blindness

Apceth begins phase II trial of engineered cell therapy to treat gastrointestinal cancer

Positive outcome from European decentralized procedure for approval of Soolantra for rosacea

Synflorix obtained Japanese approval as a pediatric pneumococcal conjugate vaccine

AG-348 assigned orphan status for pyruvate kinase deficiency

Aurigene discloses PD-1 inhibitors

Medivir present HCV polymerase NS5B inhibitors

Korean researchers describe new HGFR inhibtors

Genfit releases topline data from phase IIb study of GFT-505 for NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...